Pharmacist-Specific Guidelines for the Medical Management of GERD in Adults

Armstrong D Marshall JK Chiba N Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults — update 2004. Can J Gastroenterol 2005;19:15–35.

Vakil N van Zanten SV Kahrilas P and the Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101:1900–20.

Bardhan KD Stanghellini V Armstrong D Evaluation of GERD symptoms during therapy. Part I. Development of the new GERD questionnaire ReQuest. Digestion 2004;69:229–37.

Mönnikes H Bardhan KD Stanghellini V Evaluation of GERD symptoms during therapy. Part II. Psychometric evaluation and validation of the new questionnaire ReQuest in erosive GERD. Digestion 2004;69:238–44.

Bardhan KD Stanghellini V Armstrong D International validation of ReQuest in patients with endoscopy-negative gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2004;20:891–8.

Thomson AB Barkun AN Armstrong D The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment — Prompt Endoscopy (CADET-PE) study. Aliment Pharmacol Ther 2003;17:1481–91.

Vakil N Moayyedi P Fennerty MB Talley NJ . Limited value of alarm features in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis. Gastroenterology 2006;131:390–401.

van Zanten SJO Veldhuyzen Flook N Chiba N An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori CMAJ 2000;162 (Suppl 12):S3–S23.

Panju A Farkouh ME Sackett DL Outcome of patients discharged from a coronary care unit with a diagnosis of “chest pain not yet diagnosed.” CMAJ 1996;155:541–6.

Armstrong D Bennett J Blum A The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology 1996;111:85–92.

Lundell L Dent J Bennett J Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999;45:172–80.

DeVault KR Castell DO . Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1999;94:1434–42.

Dent J Brun J Fendrick A An evidence-based appraisal of reflux disease management — the Genval Workshop Report. Gut 1999;44 (Suppl 2):S1–16.

Broussard CN Richter JE . Treating gastro-oesophageal reflux disease during pregnancy and lactation: what are the safest therapy options? Drug Safety 1998;19:325–37.

Winbery SL Blaho KE . Dyspepsia in pregnancy. Obstet Gynecol Clin North Am 2001;28:333–50.

Richter JE . Gastroesophageal reflux disease during pregnancy. Gastroenterol Clin North Am 2003;32:235–61.

van Zanten SJO Veldhuyzen Bradette M Chiba N , for the Canadian Dyspepsia Working Group. Evidence-based recommendations for short- and long-term management of uninvestigated dyspepsia in primary care: an update of the Canadian Dyspepsia Working Group (CanDys) clinical management tool. Can J Gastroenterol 2005;19:285–303.

Einarson A Maltepe C Boskovic R Koren G . Treatment of nausea and vomiting in pregnancy. Motherisk. December 2007. Available: www.motherisk.org/prof/updatesDetail.jsp?content_id=875 (accessed July 22, 2008).

Lalkin A Magee L Addis A Loebstein R Koren G . Acid-suppressing drugs during pregnancy. Motherisk. November 1997. Available: www.motherisk.org/women/updatesDetail.jsp?content_id=297 (accessed May 11, 2008).

Navo-Ocampo AA Velazquez-Armenta EY Han JY Koren G . Use of proton pump inhibitors during pregnancy and breastfeeding. Motherisk. July 2006. Available: www.motherisk.org/women/updatesDetail.jsp?content_id=838 (accessed May 11, 2008).

Poynard T Vernisse B Agostini H . Randomized, multicentre comparison of sodium alginate and cisapride in the symptomatic treatment of uncomplicated gastro-oesophageal reflux. Aliment Pharmacol Ther 1998;12:159–65.

Shaffer EA . Gastroesophageal reflux disease. In: Gray J , ed. Therapeutic Choices, 5th ed. Ottawa, ON: Canadian Pharmacists Association; 2007:728–30.

Repchinsky C , editor. Compendium of pharmaceuticals and specialties. Ottawa, ON: Canadian Pharmacists Association; 2008:720,975.

Gillen D McColl KEL . Problems related to acid rebound and tachyphylaxis. Best Pract Res Clin Gastroenterol 2001;15:487–95.

Bell NJ Burget D Howden CW Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51 (Suppl. 1):59–67.

Chiba N de Gara CJ Wilkinson JM Hunt RH . Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997;112:1798–810.

Longstreth GF Thompson WG Chey WD Functional bowel disorders. Gastroenterology 2006;130:1480–91.

Johansson K Ask P Boeryd B Oesophagitis, signs of reflux, and gastric acid secretion in patients with symptoms of gastro-oesophageal reflux disease. Scand J Gastroenterol 1986;21:837–47.

Pujol A Grande L Ros E Pera C . Utility of inpatient 24-hour intraesophageal pH monitoring in diagnosis of gastroesophageal reflux. Dig Dis Sci. 1988;33:1134–40.

Masclee A de Best A de Graaf R Ambulatory 24-hour pH-metry in the diagnosis of gastroesophageal reflux disease. Determination of criteria and relation to endoscopy. Scand J Gastroenterol 1990;25:225–30.

Kasapidis P Xynos E Mantides A Differences in manometry and 24-H ambulatory pH-metry between patients with and without endoscopic or histological esophagitis in gastroesophageal reflux disease. Am J Gastroenterol 1993;88:1893–9.

Saraswat V Dhiman R Mishra A Naik S . Correlation of 24-hr esophageal pH patterns with clinical features and endoscopy in gastroesophageal reflux disease. Dig Dis Sci. 1994;39:199–205.

Armstrong D van Zanten SJO Veldhuyzen Barkun AN Heartburn-dominant, uninvestigated dyspepsia: a comparison of “PPI-start” and “H₂-RA-start” management strategies in primary care — the CADET-HR Study. Aliment Pharmacol Ther 2005;21:1189–202.

Katz PO Castell DO Chen Y Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover. Aliment Pharmacol Ther 2004;20:399–406.

Wilder-Smith C Backlund A Eckerwall G Effect of increasing esomeprazole and pantoprazole doses on acid control in patients with symptoms of gastro-oesophageal reflux disease. A randomized, dose-response study. Clin Drug Invest 2008;28:333–43.

Frazzoni M De ME Grisendi A Savarino V . Effective intraoesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs pantoprazole. Aliment Pharmacol Ther 2003;17:235–41.

Frazzoni M De ME Grisendi A Savarino V . Lansoprazole vs omeprazole for gastro-oesophageal reflux disease: a pH-metric comparison. Aliment Pharmacol Ther 2002;16:35–9.

Jones R Armstrong D Malfertheiner P Ducrotté P . Does the treatment of gastroesophageal reflux disease (GERD) meet patients' needs? A survey-based study. Curr Med Res Opin 2006;22:657–62.

Armstrong D van Zanten SJO Veldhuyzen Chung SA Validation of a short questionnaire in English and French for use in patients with persistent upper GI symptoms despite proton pump inhibitor (PPI) therapy: the PASS (PPI Acid Suppression Symptom) Test. Can J Gastroenterol 2005;19:350–8.

Miner P Katz P Chen Y Sostek M . Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003;98:2616–20.

Richter J Kahrilas P Johanson J Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001;96:656–65.

Kahrilas P Falk G Johnson D Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000;14:1249–58.

Castell D Kahrilas P Richter J Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002;97:575–83.

Labenz J Armstrong D Lauritsen K A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther 2005;21:739–46.

Fass R Murthy U Hayden C Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy — a prospective, randomized, multi-centre study. Aliment Pharmacol Ther 2000;14:1595–603.

Lundell L Miettinen P Myrvold H Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. J Am Coll Surg 2001;192:172–81.

Orr W Harnish M . The efficacy of omeprazole twice daily with supplemental H₂ blockade at bedtime in the suppression of nocturnal oesophageal and gastric acidity. Aliment Pharmacol Ther 2003;17:1553–8.

Ours T Fackler W Richter J Vaezi M . Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol 2003;98:545–50.

Peghini P Katz P Castell D . Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998;115:1335–9.

Fackler W Ours T Vaezi M Richter J . Long-term effect of H₂RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002;122:625–32.

Armstrong D . Persistence of gastroesophageal reflux disease: a systematic review of the literature. Gastroenterology 2008;134:S1092 [Abstract].

Dent J Talley N . Overview: initial and long-term management of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2003;17 (Suppl 1):53–7.

Pohle T Domschke W . Results of short- and long-term medical treatment of gastroesophageal reflux disease (GERD). Langenbecks Arch Surg 2000;385:317–23.

Freston J Triadafilopoulos G . Approaches to the long-term management of adults with GERD-proton pump inhibitor therapy, laparoscopic fundoplication or endoscopic therapy? Aliment Pharmacol Ther 2004;19 (Suppl 1):35–42.

Richter J . Long-term management of gastroesophageal reflux disease and its complications. Am J Gastroenterol 1997;92:30S–34S.

Donnellan C Sharma N Preston C Moayyedi P . Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2004;(4): CD003245. DOI: 10.1002/14651858.CD003245.pub2.

Lauritsen K Deviere J Bigard M Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. Aliment Pharmacol Ther 2003;17:333–41.

Labenz J Armstrong D Lauritsen K Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study. Aliment Pharmacol Ther 2005;22:803–11.

Venables TL Newland RD Patel AC Maintenance treatment for gastro-oesophageal reflux disease. A placebo-controlled evaluation of 10 milligrams omeprazole once daily in general practice. Scand J Gastroenterol 1997;32 (7):627–32.

Carlsson R Galmiche J Dent J Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther 1997;11:473–82.

Bardhan KD . Intermittent and on-demand use of proton pump inhibitors in the management of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003;98 (Suppl):S40–8.

Sjostedt S Befrits R Sylvan A Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis. Aliment Pharmacol Ther 2005;22:183–91.

Zacny J Zamakhshrary M Sketris I Systematic review: the efficacy of intermittent and on-demand therapy with histamine H₂-receptor antagonists or proton pump inhibitors for gastro-oesophageal reflux disease patients. Aliment Pharmacol Ther 2005;21:1299–312.

Lee A Stockley IH . Drug-drug interactions. In: Van Boxtel CJ Santoso B Edwards IR , editors. Drug benefits and risks: international textbook of clinical pharmacology. Hoboken, NJ: John Wiley & Sons Ltd.; 2001. p. 211–26.

Flockhart DA Desta Z Mahal SK . Selection of drugs to treat gastro-oesophageal reflux disease. The role of drug interactions. Clin Pharmacokinet 2000;39:295–309.

Gerson LB Triadafilopoulos G . Proton pump inhibitors and their drug interactions: an evidence-based approach. Eur J Gastroenterol Hepatol 2001;13:611–6.